These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27959289)

  • 1. Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.
    Connor KA
    AACN Adv Crit Care; 2016 Oct; 27(4):353-357. PubMed ID: 27959289
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 4. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New antibiotics - standstill or progress].
    Rademacher J; Welte T
    Med Klin Intensivmed Notfmed; 2017 Apr; 112(3):206-213. PubMed ID: 28314920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
    Gonzalez MD; McMullen AR; Wallace MA; Crotty MP; Ritchie DJ; Burnham CA
    Ann Lab Med; 2017 Mar; 37(2):174-176. PubMed ID: 28029009
    [No Abstract]   [Full Text] [Related]  

  • 7. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
    Rodriguez BA; Girotto JE; Nicolau DP
    Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
    [No Abstract]   [Full Text] [Related]  

  • 9. Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam: two effective antimicrobial agents against multidrug-resistant organisms except for NDM-1 isolates.
    Davido B; Senard O; de Truchis P; Salomon J; Dinh A
    Int J Infect Dis; 2017 Sep; 62():124-125. PubMed ID: 28676347
    [No Abstract]   [Full Text] [Related]  

  • 10. [New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora].
    Dibirov MD; Khachatryan NN; Isaev AI; Karsotyan GS; Alimova EE; Kostyuk EA
    Khirurgiia (Mosk); 2019; (12):74-83. PubMed ID: 31825346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy of ceftazidime-avibactam and ceftolozane-tazobactam against multidrug-resistant organisms.
    Alatoom A
    Int J Infect Dis; 2017 Sep; 62():126. PubMed ID: 28676348
    [No Abstract]   [Full Text] [Related]  

  • 12. Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings.
    Bidell MR; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1205-1215. PubMed ID: 30289995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime/Avibactam (Avycaz) -- a new intraveneous antibiotic.
    Med Lett Drugs Ther; 2015 May; 57(1469):79-80. PubMed ID: 25989198
    [No Abstract]   [Full Text] [Related]  

  • 14. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
    Durand CR; Alsharhan M; Willett KC
    Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
    Tamma SM; Hsu AJ; Tamma PD
    Paediatr Drugs; 2016 Feb; 18(1):1-11. PubMed ID: 26645401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota.
    Rashid MU; Rosenborg S; Panagiotidis G; Löfdal KS; Weintraub A; Nord CE
    Int J Antimicrob Agents; 2015 Jul; 46(1):60-5. PubMed ID: 25979639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
    Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.